In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.77 below Travere Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 370 other companies have achieved higher Quick Ratio than Travere Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1055 to 2030.

Explain Quick Ratio?
How much Cash & cash equivalents TVTX�s has?
What are TVTX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

TVTX Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	-19.79 %	-31.25 %	-20.35 %	-28.92 %	56.3 %
Y / Y Cash & cash equivalent Change	-63.15 %	-17.86 %	-12.92 %	-8.26 %	-1.8 %
Quick Ratio MRQ	0.77	2.11	2.02	1.88	1.69
TVTX's Total Ranking	# 2030	# 1055	# 241	# 987	# 0
Seq. Current Liabilities Change	21.2 %	-21.55 %	18.38 %	-28.74 %	3.88 %
Seq. Cash & cash equivalent Change	-55.52 %	-18.01 %	26.82 %	-20.34 %	-0.84 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 371
Healthcare Sector	# 671
Overall Market	# 2030

Quick Ratio Statistics
High	Average	Low
7.57	2.98	0.04
(Mar 31 2021)		(Jun 30 2013)

Financial Statements
Travere Therapeutics Inc 's Current Liabilities	$ 152 Millions	Visit TVTX's Balance sheet
Travere Therapeutics Inc 's Cash & cash equivalent	$ 118 Millions	Visit TVTX's Balance sheet
Source of TVTX's Sales		Visit TVTX's Sales by Geography

Cumulative Travere Therapeutics Inc 's Quick Ratio

TVTX's Quick Ratio for the trailling 12 Months

TVTX Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-24.95 %	-12.18 %	-2.67 %	6.85 %	24.67 %
Y / Y Cash & cash equivalent TTM Growth	-25.6 %	-10.36 %	-13.82 %	-21.34 %	-34.45 %
Quick Ratio TTM	1.68	1.9	1.83	1.79	1.69
Total Ranking TTM	# 3896	# 2885	# 1125	# 2861	# 0
Seq. Current Liabilities TTM Growth	-6.15 %	-8.55 %	-5.77 %	-7.21 %	9.83 %
Seq. Cash & cash equivalent TTM Growth	-17.37 %	-4.72 %	-3.78 %	-1.78 %	-0.45 %

Quick ratio ranking by company, industry and sector >> Back to TVTX Financial Strength Comparisons >> Go to Compare TVTX Quick Ratio to its Competitors

News about Travere Therapeutics Inc Quick Ratio

Travere Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, May 15, 2024 - Travere Therapeutics, Inc. (NASDAQ: TVTX) has recently disclosed the granting of inducement equity grants to several new employees, a move aimed at attracting top talent to fuel the growth and innovation of the company. The Compensation Committee of Travere s Board of Directors authorized these grants on May 10, 2024, consisting of inducement stock options and inducement restricted stock units (RSUs) for a total of 51,500 shares of its common stock.
Specifically, the inducement grants included stock options that will allow the purchase of 25,000 shares of common stock, as well as RSUs covering 26,500 shares of Travere s common stock. Although these grants will be subject to the terms outlined in Traveres 2018 Equity Incentive Plan (2018 Plan), it should be noted that they were granted outside of the 2018 Plan. Instead, they were issued as inducements material to the successful recruitment of these new employees in accordance with Nasdaq Listing Rule 5635(c)(4).

On the trailing twelve months basis In spite of the year on year decrease in TVTX's Current Liabilities to $152.03 millions, cumulative Quick Ratio to 1.68 below the TVTX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 432 other companies have achieved higher Quick Ratio than Travere Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2885 to 3896.

Explain Quick Ratio?
How much Cash & cash equivalents TVTX�s has?
What are TVTX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 433
Healthcare Sector	# 886
Within the Market	# 3896

trailing twelve months Quick Ratio Statistics
High	Average	Low
6	3	0.15
(Mar 31 2021)		(Jun 30 2013)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Oragenics Inc	2.12	$ 3.864 Millions	$ 1.822 Millions
Pacira Biosciences inc	2.06	$ 251.031 Millions	$ 122.011 Millions
Genelux Corporation	2.05	$ 29.870 Millions	$ 14.590 Millions
Opko Health Inc	2.01	$ 300.761 Millions	$ 149.367 Millions
Corcept Therapeutics Inc	2.00	$ 308.197 Millions	$ 153.802 Millions
Clene Inc	2.00	$ 9.700 Millions	$ 4.852 Millions
Blue Water Vaccines Inc	2.00	$ 5.942 Millions	$ 2.974 Millions
Vertex Pharmaceuticals Inc	1.99	$ 7,852.400 Millions	$ 3,937.900 Millions
Metavia Inc	1.99	$ 12.636 Millions	$ 6.346 Millions
Connect Biopharma Holdings Limited	1.93	$ 31.500 Millions	$ 16.301 Millions
Amarin Corp Plcuk	1.92	$ 314.850 Millions	$ 164.195 Millions
Mustang Bio inc	1.91	$ 15.150 Millions	$ 7.918 Millions
Therapeuticsmd Inc	1.84	$ 9.189 Millions	$ 5.003 Millions
Fortress Biotech Inc	1.81	$ 196.576 Millions	$ 108.829 Millions
Maravai Lifesciences Holdings Inc	1.77	$ 70.091 Millions	$ 39.519 Millions
Decoy Therapeutics Inc	1.77	$ 8.289 Millions	$ 4.680 Millions
Hyperion Defi inc	1.75	$ 9.637 Millions	$ 5.509 Millions
Verastem Inc	1.75	$ 136.400 Millions	$ 78.130 Millions
Urogen Pharma Ltd	1.74	$ 108.000 Millions	$ 61.915 Millions
Pyxis Oncology Inc	1.72	$ 47.141 Millions	$ 27.474 Millions
Ernexa Therapeutics Inc	1.71	$ 5.028 Millions	$ 2.932 Millions
Lantern Pharma Inc	1.70	$ 7.361 Millions	$ 4.323 Millions
Nuvectis Pharma inc	1.67	$ 22.160 Millions	$ 13.294 Millions
Quoin Pharmaceuticals Ltd	1.63	$ 10.800 Millions	$ 6.613 Millions
Mallinckrodt Plc	1.63	$ 1,075.800 Millions	$ 660.600 Millions
Macrogenics Inc	1.59	$ 173.305 Millions	$ 108.815 Millions
Fibrobiologics Inc	1.59	$ 3.515 Millions	$ 2.213 Millions
Sarepta Therapeutics Inc	1.57	$ 788.489 Millions	$ 502.908 Millions
Revium Rx.	1.55	$ 1.506 Millions	$ 0.971 Millions
Liquidia Corporation	1.50	$ 284.181 Millions	$ 189.298 Millions

Date modified: 2026-09-12T06:12:36+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.